2024 VKTX股份猛增323%,市场上限达到88亿美元,尽管围绕第三阶段的研究存在不确定性。 2024 VKTX shares surge 323%, market cap reaches $8.8 billion, despite uncertainties surrounding phase 3 study.
维京病治疗(VKTX)正吸引人们对其双双GLP-1和GIP受体激动剂VK2735的兴趣,其目的是比现有的GLP-1药物更有效地治疗肥胖症。 Viking Therapeutics (VKTX) is attracting interest for its dual GLP-1 and GIP receptor agonist, VK2735, which aims to treat obesity potentially more effectively than existing GLP-1 medications. 2024年,VKTX股票猛涨323%,将市场上限提高到88亿美元。 In 2024, VKTX shares surged 323%, boosting its market cap to $8.8 billion. 虽然该公司的金融实力很强,但投资者被警告股票的投机性质及其第3阶段研究的不确定性,这表明他们更喜欢诺沃·诺迪斯克等既有竞争对手。 While the company's financials are strong, investors are cautioned about the speculative nature of the stock and the uncertainties of its phase 3 study, suggesting a preference for established competitors like Novo Nordisk.